Replacement of coagulation factors in liver or multiple organ dysfunction

Area of Science:

• Hematology
• Transfusion Medicine
• Critical Care

Background:

• Hemostasis alterations in multiple organ dysfunction (MOD) often necessitate non-specific replacement therapy with fresh frozen plasma (FFP).
• Advances in virus inactivation and plasma derivative component identification have increased the use of high-purity blood coagulation factor concentrates.
• Concerns regarding activated factors and thrombogenicity have been significantly mitigated.

Purpose of the Study:

• To evaluate the role of high-purity blood coagulation factor concentrates in managing hemostasis in MOD.
• To explore the potential for specific replacement therapy in MOD.

Main Methods:

• Review of current practices in hemostasis management for MOD.
• Analysis of the benefits and safety of high-purity blood coagulation factor concentrates.
• Comparison of specific factor concentrates versus non-specific FFP therapy.

Main Results:

• High-purity blood coagulation factor concentrates are increasingly utilized due to refined manufacturing processes.
• These concentrates offer a defined factor content, enhancing therapeutic precision.
• The thrombogenic risk associated with activated factors has been substantially reduced.

Conclusions:

• High-purity blood coagulation factor concentrates represent a shift towards specific replacement therapy in MOD.
• This approach complements traditional FFP therapy, offering improved management of hemostatic complexity.
• Future applications promise tailored treatments for single or multiple organ dysfunction.